To report on timeliness to study initiation, enrolment, compliance and retention rates of a prospective, randomized pilot study with participants with HIV, aged ≥18 and on antiretroviral therapy and randomly assigned to cannabidiol (CBD) ± Δ9-tetrahydrocannabinol (THC) capsules for 12 weeks with the primary objective being to assess safety and tolerability.